Free Trial

Acrivon Therapeutics (ACRV) SEC Filings & 10K Form

Acrivon Therapeutics logo
$1.32 -0.03 (-2.22%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.35 +0.03 (+2.20%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Acrivon Therapeutics SEC Filings

DateFilerForm TypeView
06/17/2025
7:17 PM
Acrivon Therapeutics (Issuer)
Kolchinsky Peter (Reporting)
RA Capital Healthcare Fund LP (Reporting)
RA CAPITAL MANAGEMENT, L.P. (Reporting)
RA Capital Nexus Fund II, L.P. (Reporting)
Shah Rajeev M. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:48 PM
Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:49 PM
Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:54 PM
Acrivon Therapeutics (Issuer)
Shacham Sharon (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:57 PM
Acrivon Therapeutics (Issuer)
TOMSICEK MICHAEL JOHN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
5:04 PM
Acrivon Therapeutics (Issuer)
DiRocco Derek (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/17/2025
4:21 PM
Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025
3:05 PM
Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SCHEDULE 13G/A
05/23/2025
3:58 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
05/15/2025
4:24 PM
Acrivon Therapeutics (Subject)
CITADEL ADVISORS LLC (Filed by)
Form SCHEDULE 13G/A
05/14/2025
3:47 PM
Acrivon Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
05/14/2025
3:16 PM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/01/2025
7:21 PM
Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
Form SCHEDULE 13G/A
05/01/2025
6:07 PM
Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/29/2025
6:26 PM
Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/25/2025
7:34 AM
Acrivon Therapeutics (Filer)
Form ARS
04/25/2025
7:30 AM
Acrivon Therapeutics (Filer)
Form DEF 14A
04/25/2025
7:32 AM
Acrivon Therapeutics (Filer)
Form DEFA14A
04/21/2025
3:22 PM
Acrivon Therapeutics (Issuer)
Mirza Mansoor Raza (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/03/2025
3:32 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2025
3:28 PM
Acrivon Therapeutics (Issuer)
Levy Adam D. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
04/03/2025
3:30 PM
Acrivon Therapeutics (Issuer)
Levy Adam D. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/28/2025
8:08 AM
Acrivon Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
03/27/2025
3:48 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/25/2025
4:15 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/14/2025
3:44 PM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/04/2025
4:36 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
4:28 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2025
4:31 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:52 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:53 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:54 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:55 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2025
3:59 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:04 PM
Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
Masson Kristina (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:06 PM
Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:08 PM
Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:10 PM
Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/27/2024
5:11 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2024
6:06 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/13/2024
6:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
A grave, grave error. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

10/21/2024
3:22 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
10/11/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/03/2024
5:49 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/16/2024
5:43 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/16/2024
3:52 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/16/2024
3:53 PM
Acrivon Therapeutics (Issuer)
Peterson Katharine (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2024
7:00 AM
Acrivon Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2024
6:36 AM
Acrivon Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/19/2024
3:20 PM
Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:ACRV) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners